TheraLife warning letter
This article was originally published in The Tan Sheet
Executive SummaryFDA says claims for TheraLife's Wrist, Fatigue, Neck and Back & Leg products classify them as unapproved new drugs and are misleading. The products make drug claims such as, "Treats painful and chronic conditions often experienced by computer keyboard and mouse users," according to FDA. On its Web site, the firm also says it adheres to all FDA regulatory guidelines and provides a link to FDA's 30-day structure/function claims. FDA says the company is not in compliance and is misleading by linking to FDA's site. TheraLife has 15 days to correct the violations, the agency says...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.